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Thymidine phosphorylase may be overexpressed in both neoplastic cells and tumor stromal cells in a variety of malignancies.
Our study explores thymidine phosphorylase expression in lymph nodes (LNs) from patients with mycosis fungoides (MF) or
S´ ezary syndrome (SS). In MF/SS, the LNs may have a pathologic diagnosis of either dermatopathic lymphadenopathy (LN-DL)
or involvement by MF/SS (LN-MF). We performed immunohistochemical staining on MF/SS lymph nodes using antibodies to
thymidine phosphorylase, CD68, CD21, CD3, and CD4. In both LN-DL and benign nodes, thymidine phosphorylase staining
was noted only in macrophages, dendritic cells, and endothelial cells. In LN-MF, thymidine phosphorylase expression was also
noted in subsets of intermediate to large neoplastic T cells. Concurrent CD68, CD21, CD3, and CD4 staining supported the above
observations. Similar results were noted in the skin and in LN-MF with large cell transformation. Other T-cell lymphomas were
also examined (total 7 cases); only enteropathy-type T-cell lymphoma (1 case) showed TP positivity in neoplastic T lymphocytes.
WedemonstratedthatthymidinephosphorylasestainingispresentinneoplasticTcellsinmycosisfungoides.Theexactmechanism
needs further investigation.
1.Introduction
Mycosis fungoides (MF) and S´ ezary syndrome (SS) are the
most common types of cutaneous T-cell lymphomas and
representclonalproliferationsofneoplasticCD4+ Tcells.MF
initially develops in an indolent fashion as a skin-conﬁned
disease. However, with progressive disease, malignant T
cells involve skin-associated lymph nodes (LNs), thereby
indicating a higher clinical stage [1] .T h ep r e s e n c eo f
circulating neoplastic cells in the peripheral blood is the
hallmark of SS. Lymphadenopathy in MF/SS ranges from
dermatopathic lymphadenopathy (DL), a reactive pattern
associated with various chronic skin diseases, to clearcut
involvement by malignant T cells that results in partial or
complete eﬀacement of lymph node structure (MF-LN).
Smaller numbers of atypical or neoplastic cells may be found
in DL, but the prognostic signiﬁcance is unclear [2].
Various mechanisms have been implicated in the com-
plexityoftumorigenesis,includingimbalanceofsubsetsofT-
regulatory cells and cytokine levels [3–5] and dysregulation
of chemokine receptors, including CCR4, CXCR4, CCR10
[6–8], and P16 [9]. However, the mechanism of tumorigen-
esis has not been well established. Thymidine phosphorylase
(TP), also known as platelet-derived endothelial cell growth
factor, may be overexpressed in both neoplastic cells and
tumor stromal cells in a variety of cancers, including breast
[10], colorectal [11], gastric [12], esophageal [13], lung [14],
andbladder[15].TPisthoughttopromotetumorigenesisby
inducing tumor cell growth through both inhibition of the
apoptosis pathway [16–19] and tumor angiogenesis via the
PI3K-mTOR (phosphoinositide 3-kinase-mammalian target
of rapamycin) pathway [20]. In addition, TP expression in
neoplastic cells can be used as a biomarker to predict
response to chemotherapy and survival in esophageal squa-
mous cell carcinoma, breast cancer, and other cancers [21,
22]. However, few studies regarding the role of TP in
hematopoietic malignancy have been reported. We studied
TP expression in MF-LN.2 Advances in Hematology
2.MaterialsandMethods
Experimental protocols were approved by the Institutional
Review Board of Drexel University College of Medicine.
Archived paraﬃn blocks with LNs from 51 patients with
MF and SS (1991–2010) were used to construct a tissue
microarray. Thirty-four of 51 MF/SS patients had a patho-
logic diagnosis of DL and 17 had partially or completely
eﬀaced LNs by MF or SS. Immunohistochemical (IHC)
staining using antibodies to TP, CD68, CD21, CD3, and CD4
was performed. Nine cases of benign LNs were included as
control. Archived unstained skin slides were also used to test
TP expression from patients with MF in skin-conﬁned stage
(5 cases), MF-LN with large cell transformation (1 case),
extranodal NK/T-cell lymphoma (1 case), peripheral T-cell
lymphoma (2 cases), enteropathy-type T-cell lymphoma (1
case), angioimmunoblastic T-cell lymphoma (2 cases), and
syringotropic cutaneous T-cell lymphoma (1 case).
For IHC staining, the slides were deparaﬃnized and
rehydratedinaseriesofalcohol.IHCstainingwasperformed
using an automated system (Dako Autostainer, Univer-
sal Staining System Autostainer, Carpinteria, Calif). The
primary antibodies used in this study were TP (1:1000;
Novus Biologicals, Littleton, Colo), CD3 (1:100; Dako),
CD4 (1:10; Dako), CD68 (1:2000; Dako), and CD21 (1:50;
Vector,Burlingame,Calif),usedfortissuemicroarrayblocks.
Markers used for skin slides were CD4 and TP; TP was used
as a marker for all other T-cell lymphomas.
3. Results andDiscussion
In control LNs, TP staining was noted only in macrophages,
dendritic cells, and endothelial lining cells, with a cytoplas-
mic and nuclear staining pattern. Small lymphocytes were
negative for TP. A similar TP IHC staining pattern was
noted in DL. Positive TP immunostaining was noted in
30% to 80% of intermediate to large neoplastic T cells in
all MF-LN cases with a predominantly cytoplasmic staining
pattern (Figure 1). Small lymphocytes were negative for TP,
and macrophages, dendritic cells, and endothelial lining
cells were again positive for TP. Concurrent CD68 and
CD21 staining supported the above observations (Figure 1).
IHC staining in MF-skin (Figures 2(a)–2(c)) and in MF-
LN with large cell transformation (Figure 2(d)) showed a
similar staining pattern. Positive TP staining was noted in
the neoplastic T cells in one case of enteropathy-type T-
cell lymphoma (Figure 3). In other lymphoma cases (extra-
nodal NK/T-cell lymphoma, peripheral T-cell lymphoma,
angioimmunoblastic T-cell lymphoma, and syringotropic
cutaneous T-cell lymphoma) positive TP staining was only
noted in macrophages and endothelial cells.
Thymidine phosphorylase was found to be present in
benign tissue, such as spleen, liver, lymph nodes, esophagus,
and rectum, and in a variety of cells, including macrophages,
stromal cells, glial cells, endothelial cells, and reticulocytes,
with a cytoplasmic or nuclear pattern [23, 24]. Studies
have shown that TP is overexpressed in both neoplastic
cells and tumor stromal cells in a variety of malignancies
such as breast, colorectal, gastric, esophageal, lung, and
bladder. We demonstrated that TP expression is present not
only in macrophages, dendritic meshworks, and endothelial
lining cells but also in intermediate to large neoplastic T
lymphocytes.
To our knowledge, 2 previous studies have reported
on TP expression in hematopoietic malignancies. In 1990,
Yoshimura et al. [24], using immunoblotting, demonstrated
higher TP expression in tissues from patients with T- and
B-cell malignant lymphomas than from those with lym-
phoblastic and myeloblastic leukemias. However, they did
not determine which cells expressed TP in the hematopoietic
malignancies. In 1997 Doussis-Anagnostopoulou et al. [25]
used IHC staining to test TP expression in a variety of tissues
from patients with hematopoietic malignancies. Malignan-
cies tested included Hodgkin’s lymphoma (20 cases), small
lymphocytic lymphoma (2 cases), mantle cell lymphoma (1
case), follicular lymphoma (10 cases), diﬀuse large B-cell
lymphoma (8 cases), peripheral T-cell lymphoma (7 cases),
intestinal T-cell lymphoma (1 case), and anaplastic large T-
cell lymphoma (1 case). TP expression was noted only in the
meshwork of dendritic cells, macrophages, and endothelial
cells but not in neoplastic cells. The authors commented
that the expression of TP in dendritic cells and macrophages
might be due to cytokine production and dysregulation
contributing to the tumor microenvironment.
We have demonstrated that TP expression is present
in neoplastic T cells in LNs, skin involved with MF or SS
(Table 1). This phenomenon may be due to changes intrinsic
to the tumor cells themselves, or it may reﬂect interactions
between the tumor microenvironment and the lymphoma
cells. The exact mechanism of increased TP expression
in lymphoma cells needs further investigation and may
have therapeutic implications. Data are scarce regarding TP
expressioninotherneoplasticT-celllymphomas,andfurther
study would be worthwhile.
Abbreviations
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IHC: Immunohistochemical
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TP: Thymidine phosphorylase.
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Figure 1: Immunohistochemical staining of thymidine phosphorylase(TP) expression and related markers in benign lymph node (a) and in
lymph node with malignant mycosis fungoides/S´ ezary syndrome cells (LN-MF) (b–g). (a) In benign lymph node, TP expression highlights
the meshwork of macrophages (arrow in inset; 400x) and endothelial cells (arrowhead in inset; 400x). (b) LN-MF: hematoxylin and eosin
(H&E) stain. (c) CD3 highlights the malignant T cells and reactive T cells in LN-MF. (d) CD4 is weakly expressed in the malignant T cells
in LN-MF. (e) CD68 highlights the macrophages in LN-MF. (f) CD21 is negative in this case of LN-MF. (g) TP highlights the macrophages
(cytoplasmic/nuclear pattern, arrowhead in inset 1; 400x) and the malignant T cells (cytoplasmic pattern, arrow in inset 2; 400x) in a
cytoplasmic staining pattern. Multiple mitotic ﬁgures are also noted in the malignant T cells. Images are from an Olympus BX41 microscope
(Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada).4 Advances in Hematology
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Figure 2: Immunohistochemical stain of thymidine phosphorylase (TP) expression and related markers in skin-involved mycosis fungoides
(MF-skin) and in a case of mycosis fungoides/S´ ezary syndrome cells with involved lymph nodes (LN-MF) with large cell transformation.
(a) MF-skin: hematoxylin and eosin (H&E) stain. (b) MF-skin: CD4 highlights the malignant T cells in the epidermis. (c) MF-skin: TP
expression is noted in malignant T cells (arrow in inset; 400x), squamous cells, and endothelial cells (arrowhead in inset; 400x). (d) An MF
lymph node with large cell transformation is demonstrated: H&E stain. (e) TP stain shows positive immunoactivity in the transformed large
neoplastic T cells (arrow in inset; 400x); macrophages are indicated by arrow in inset (400x). Images are from an Olympus BX41 microscope
(Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada).
Table 1: Thymidine phosphorylase immunohistochemical stain (cytoplasmic/nuclear).
Small lymphocytes Neoplastic cells Macrophages and dendritic cells Endothelial cells
Benign LN Negative N/A Positive Positive
MF-LN Negative Positive Positive Positive
LN: lymph nodes; MF-LN: lymph nodes involved with mycosis fungoides or S´ ezary syndrome.Advances in Hematology 5
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Figure 3: Immunohistochemical stain of thymidine phosphorylase (TP) expression in a gastrointestinal biopsy specimen from a patient
with enteropathy-type T-cell lymphoma. (a) Hematoxylin and eosin stain. (b) TP stain highlights neoplastic T cells (arrow in inset; 400x).
Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC,
Canada).
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